Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline's Arexvy vaccine to include adults aged 50 to 59 who ... Read More
GSK to acquire Aiolos Bio to expand respiratory treatment portfolio
GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) have announced a significant agreement, where GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focusing on ... Read More
GSK gets Jesduvroq FDA approval for anaemia of chronic kidney disease
GSK has secured the approval of the US Food and Drug Administration (FDA) for the company’s Jesduvroq (daprodustat) for anaemia of chronic kidney disease (CKD) ... Read More
Wave Life Sciences, GSK partner on oligonucleotide-based gene therapies
Wave Life Sciences and GSK have forged a partnership to discover and develop oligonucleotide therapeutics, focusing on new genetic targets, for respiratory diseases. The discovery ... Read More